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Abstract Yersinia pseudotuberculosis-derived mitogen (YPM) 
is the unique Gram-negative bacillary superantigen known. In 
order to identify the regions on the YPM molecule involved in its 
superantigenic activity, seven overlapping peptides of the entire 
YPM molecule were synthesized and tested to evaluate their 
effects on the YPM-induced proliferation of human peripheral 
blood lymphocytes. A peptide corresponding to the N-terminal 
amino acid sequence (1-23) was found to inhibit YPM-induced 
lymphocyte proliferation in a concentration-dependent manner. 
The N-terminal peptide was found to show no inhibition of the 
proliferation induced by the other superantigen (staphylococcal 
enterotoxin B) or the other T-cell mitogen pertussis toxin, 
indicating that the inhibition is specific to YPM-induced 
proliferation. Thus, we have identified the N-terminal region 
(1-23) of the YPM as one of the functional regions responsible 
for its superantigenic activity. 
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1. Introduction 
Yersinia pseudotuberculosis-derived mitogen (YPM) is 
known as a superantigen which is a highly potent immuno- 
stimulatory molecule [1-6]. Unlike conventional peptide anti- 
gen, a superantigen binds directly as an intact protein to ma- 
jor histocompatibility complex (MHC) class II molecules on 
antigen-presenting cells at a site distinct from the antigen 
binding groove. The superantigen/MHC complex then reacts 
with the T-cell receptors (TCR) through the particular 13 chain 
of a variable region (VIS), rather than with the normal anti- 
gen-binding roove on TCR. Therefore, each superantigen 
reacts with all T-cells that express a particular VI3 gene. The 
repertoire of VI3 activated has a pattern that is characteristic 
for each superantigen. The result of these interactions i pro- 
liferation of a large number of T-cells with consequent release 
of cytokines. This ability of superantigens directly accounts 
for their pathogenic effects and clinical symptoms of the in- 
fection [7,8]. 
Several bacterial superantigens, uch as toxic shock syn- 
drome toxin-l, staphylococcal enterotoxins and streptococcal 
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pyogenic exotoxins, are known. Although almost all of mem- 
bers are produced by the Gram-positive cocci Staphylococcus 
aureus and Streptococcus pyogenes [9], YPM is the only 
known Gram-negative bacillary superantigen whose primary 
structure substantially differs from other bacterial superanti- 
gens [4-6]. 
In the present study, we have used a competitive inhibition 
approach using synthetic YPM peptide fragments for identi- 
fication of the functional sequences on the YPM molecule 
involved in the proliferation of human peripheral blood lym- 
phocytes. These findings provide insight into how YPM func- 
tions as a superantigen. 
2. Materials and methods 
2.1. Superantigens and pertussis toxin 
YPM was purified from the cell lysate of a Y. pseudotuberculosis 
strain by the previously reported procedure [4]. Staphylococcal enter- 
otoxin B (SEB) and pertussis toxin (PT) were obtained from Sigma 
Chemical (St. Louis, MO, USA). 
2.2. Peptide synthesis 
Overlapping peptides corresponding to the entire sequence of YPM 
were synthesized by using a PerSeptive Biosystems 9050 peptide 
synthesizer, The peptide chains were elongated stepwise on polyethyl- 
ene glycol polystyrene r sin with 4-fold equivalent of an equimolar 
mixture of 9-fluorenylmethoxycarbonyl (Fmoc)-amino acid and O- 
(7-azabenzotriazol- 1-yl)- 1,1,3,3-tetramethyluronium hexafluorophos- 
phate in N,N-dimethylformamide (DMF) containing 8.5% diisopro- 
pylethylamine. The Fmoc group was removed by treatment with 2% 
1,8-diazabicyclo[5,4-O]undec-7-ene in DMF. In general, the protected 
peptide resin was treated with a mixture of trifluoroacetic acid (TFA)/ 
thioanisole/m-cresol/1,2-ethanedithiol (90/5/3/2, v/v) for 1 h at room 
temperature. After removal of TFA, the crude peptides were extracted 
with 1 M acetic acid, and then washed with diethyl ether. The syn- 
thetic peptides were purified by reversed-phase high-performance li- 
quid chromatography (RP-HPLC). 
2.3. Peptide competition studies 
Human peripheral blood mononuclear cells (PBMC) were obtained 
from heparinized peripheral blood of healthy donors by density gra- 
dient centrifugation using Ficoll-Paque (Pharmacia Biotech, Uppsala, 
Sweden). PBMC suspended in RPMI 1640 medium with 100 lag/ml of 
streptomycin, 100 U/ml of penicillin and 10% (v/v) of fetal bovine 
serum were dispensed into a 96-well microtiter plate at a density of 
2× 10 ~ cells per well (200 Ixl). To assess the ability of peptides to 
inhibit superantigen-induced proliferation, peptides were added to 
the wells. Then, the superantigen (YPM or SEB) or PT was added 
at a final concentration f 100 pg/ml or 2.5 I.tg/ml, respectively. The 
PBMC were incubated for 72 h and pulsed with 37 kBq of [methyl- 
ZH]thymidine per well for the final 7 h of incubation. The cells were 
harvested onto glass fiber filters and the [methyl-SH]thymidine incor- 
poration of ceils was determined. 
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3 Results  and discussion 
o 
(1-23) (19-41) (37-59) (55-77) (73-95) (91-113) (109-131) 
YPM Peptide Fragments 
F g. 1. Inhibition of YPM-induced proliferation of PBMC by syn- 
tt etic peptide fragments of YPM. YPM peptide fragments were 
u,ed at a final concentration f 50 BM. The superantigen YPM was 
u,ed at a final concentration of 100 pg/ml. Data are presented as 
tl e relative value (%) of net cell proliferation in the presence of 
PM and an indicated peptide as compared with that in the pres- 
ence of YPM alone. Each bar represents the mean_+ S.E. of six indi- 
v dual experiments. 
In an attempt o relate structure to function, seven over- 
l ipping peptides of the entire YPM molecule were chemically 
s 'nthesized. The amino acid sequences of the seven peptide 
f.r agments are presented in Table 1. Synthetic peptides purified 
b ¢ RP-HPLC were characterized by amino acid analysis, Ed- 
n~an degradation and fast atom bombardment mass spectro- 
metry, giving the expected ata (not shown). Of all the pep- 
t~des at a concentration of 50 gM tested for stimulation of 
PBMC proliferation, no peptide showed a significant increase 
c ¢er the normal value. 
The synthetic peptides at a concentration of 50 BM were 
e ~amined for direct functional competition with YPM for in- 
h ~bition of human PBMC proliferation stimulated by YPM. It 
as observed that only the peptide YPM(l -23) was able to 
s'gnificantly inhibit the YPM-induced proliferation (Fig. 1). 
[~ose-response tudy of this peptide showed a significant in- 
hibition of YPM-induced proliferation at a concentration as 
1, ,w as 10 pM (Fig. 2). Fifty percent inhibition of the prolif- 
e ation was observed for the peptide YPM(1-23) at a concen- 
t:ation of 50 ]aM. These results suggest hat the N-terminal 
"1 ible 1 
Amino acid sequences of the synthetic YPM peptide fragments 
10 100 1000 
[Peptide YPM-(1-23)]/~M 
PM(1-23) 
PM(19~l) 
5 PM(37 59) 
5 PM(55-77) 
"~ PM(73-95) 
PM(91 113) 
PM(109-131) 
TDYDNTLNSIPSLRIPNIATYTG 
ATYTGTIQGKGEVA* IIGNKEGKT 
KEGKTRGGELYAVLHSTNVNADM 
VNADMTLILLRNVGGNGWGEIKR 
GEIKRNDIDKPLKYEDYYTSGLS 
TSGLSWIWKIKNNSSETSNYSLD 
NYSLDATVHDDKEDSDVLTKA* PV 
* \lanine residue was substituted for two cysteine residues (Cys 32 and 
(ys129). 
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region at residues 1-23 on the YPM molecule is a region 
responsible for the induction of PBMC proliferation by YPM. 
The peptide YPM(1-23) was tested with the other super- 
antigen SEB or with the other T-cell mitogen PT to determine 
if the displayed inhibitory effect is specific to YPM. The pep- 
tide at a concentration as high as 200 gM was unable to 
inhibit the SEB-induced or PT-induced PBMC proliferation 
(data not shown), indicating that the inhibitory effect of the 
peptide YPM(1-23) is specific to the YPM-induced prolifera- 
tion. 
In the present study, we have identified through competi- 
tion studies using synthetic peptide fragments that a region of 
YPM encompassing amino acid residues 1-23 is involved in 
the induction of human PBMC proliferation. Neither the N- 
terminal sequence nor the other regions of the other super- 
antigen molecules were identical to the N-terminal sequence 
(1-23) of YPM [4]. Several investigators showed the sequences 
that are important for superantigenic a tivity of Gram-posi- 
tive coccal superantigens using synthetic peptide fragments 
[10-14], the present study performed the characterization of
the bacterial superantigen produced by a Gram-negative ba- 
cillus. It is also the first report of the structure-function rela- 
tionship of YPM. 
The use of synthetic peptide fragments i valuable in studies 
of protein-protein teraction, but a potential problem exists. 
Only a small percentage of peptide may mimic the binding site 
at any one time; thus, a large molar excess of peptide may be 
needed to demonstrate the inhibition. In addition to this, if 
the three-dimensional structure of the binding site is specific 
by virtue of its conformation, then a synthetic peptide may 
not mimic the binding site. Therefore, the results in the pre- 
sent study demonstrate that the N-terminal region (1-23) of 
YPM is one of the regions responsible for the superantigenic 
activity, but not only one. 
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Fig. 2. Concentration-dependent inhibition of the peptide YPM(1- 
23) to YPM-induced PBMC proliferation. The superantigen YPM 
was used at a final concentration f 100 pg/ml. Data are presented 
as the relative value (%) calculated by the formula as IO0(A--B)/C; 
A and B: gross of radiolabel incorporated by cell proliferation in- 
duced by YPM in the presence (B) and the absence (A) of the pep- 
tide YPM(I~3); C: net of radiolabel incorporated by cell prolifera- 
tion induced by YPM alone. Each bar represents the mean + S.E. of 
six individual experiments. 
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In order to stimulate T-cells, a superantigen has to interact 
with both the MHC class II molecule and the VI3 domain of 
TCR. Therefore, two kinds of interface are present on a 
superantigen molecule, one is for the class II MHC molecule 
and the other is for the TCR VI3 domain [7,8]. At present, we 
cannot conclude whether the N-terminal region of the YPM 
molecule constitutes the interface for the class II MHC mole- 
cule, the VI3 domain of TCR, or both. 
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